Document is current
Any future updates will be listed below
-
Authors
Evrard, Diane https://orcid.org/0000-0003-2462-4902
Beaufrère, Aurélie https://orcid.org/0000-0002-0206-058X
Dumont, Clément
Louërat, Séréna
Chaud, Adrien
Guyard, Alice https://orcid.org/0000-0002-2406-3079
Laouirem, Samira
Albuquerque, Miguel
Tijeras-Raballand, Annemilaï
Couvelard, Anne
Paradis, Valérie
Halimi, Caroline https://orcid.org/0000-0003-1586-3637
Raymond, Éric
Hourseau, Muriel
Faivre, Sandrine https://orcid.org/0000-0002-1590-485X
-
Funding
Funding for this research was provided by:
Fondation Nelia et Amadeo Barletta
Fondation de l’Avenir
- License Information
-
More Information
Article History
Received: 6 August 2025
Accepted: 19 December 2025
First Online: 27 January 2026
Declarations
:
: D.E. reports serving as a consultant for Merck Sharp and Dohme and Merck Serono. A.T. reports serving as a consultant for Onward therapeutics. C.D. reports serving as a consultant for Bristol-Myers Squibb, Pfizer, Astellas Pharma, Bayer, Merck Serono, and Ipsen. E.R. reports serving as a consultant for SCOR, Genoscience Pharma, StromaCare, and Onward therapeutics and is a shareholder of SCOR, Genoscience Pharma, StromaCare, and Axoltis. S.F. declares research support from Adlai Nortye, Merck Sharp and Dohme and Bristol-Myers Squibb and reports serving as a consultant for Merck Sharp and Dohme and Bristol-Myers Squibb. A.B., S.La., C.H., A.Co., V.P., M.H., A.G., S.Lo., M.A., and A.Ch. Have no relevant financial or non-financial interests to disclose.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of University Paris Cité, IRB 00006477- July 30, 2024 retrospectively registered.
: Informed consent was obtained from all individual participants included in the study.
